Status:
COMPLETED
Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
The intake of high doses of corticosteroids is known to play an important role in the weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is a drug known for its ...
Eligibility Criteria
Inclusion
- Long duration treatment with corticosteroids (started or ongoing)
Exclusion
- History of osteogenesis imperfecta, multiple myeloma or Paget's disease
- History of Hyperparathyroidism, hyperthyroidism
- History of Osteomalacia
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
802 Patients enrolled
Trial Details
Trial ID
NCT00100620
Start Date
June 1 2004
End Date
April 1 2007
Last Update
May 17 2017
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Education and research on Therapeutics (CERTs) of Musculoskeletal Disorders
Birmingham, Alabama, United States, 35294-3708
2
United Osteoporosis Centers
Gainesville, Georgia, United States, 30501
3
Osteoporosis & Clinical Trials
Cumberland, Maryland, United States, 21502
4
University of Ohio
Columbus, Ohio, United States, 43210